New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 11:12 AM.

  1. #1 cafead, Apr 25, 2018 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,925
    Likes Received:
    3
    via Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), announced on 4/24/18 that new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. The data demonstrated that patients experienced even further reductions in migraine following the third and fourth quarterly infusions at both dose levels (100mg and 300mg) of eptinezumab, Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP).

    article source
     
    Quote

Reply to Thread